CORCEPT THERAPEUTICS INC Revenue (ASC 606)

Quick Answer

CORCEPT THERAPEUTICS INC reported Revenue (ASC 606) of $761.41 million for fiscal year 2025.

CORCEPT THERAPEUTICS INC Revenue (ASC 606) — Annual History

Fiscal Year Revenue (ASC 606) YoY Change
2025 $761.41M +12.8%
2024 $675.04M +39.9%
2023 $482.38M +20.0%
2022 $401.86M +9.8%
2021 $365.98M +3.4%
2020 $353.87M +15.5%
2019 $306.49M +22.0%
2018 $251.25M +57.8%
2017 $159.20M +95.8%
2016 $81.32M

Quarterly Revenue (ASC 606)

Quarter Ending Revenue (ASC 606) YoY QoQ
September 30, 2025 $207.64M +13.7% +6.8%
June 30, 2025 $194.43M +18.7% +23.7%
March 31, 2025 $157.21M +7.1% -13.9%
September 30, 2024 $182.55M +47.7% +11.4%
June 30, 2024 $163.80M +39.1% +11.6%
March 31, 2024 $146.81M +39.0% +18.8%
September 30, 2023 $123.60M +21.5% +5.0%
June 30, 2023 $117.72M +13.9% +11.4%
  • CORCEPT THERAPEUTICS INC showed an increase of +12.8% in Revenue (ASC 606) compared to the prior fiscal year.
  • Over the 2016–2025 period, CORCEPT THERAPEUTICS INC’s revenue (asc 606) has grown by 836.3% (from $81.32 million to $761.41 million).
  • The most recent figure is from CORCEPT THERAPEUTICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment